Carmichael S. Roberts Jr.

Carmichael S. Roberts Jr. is a general partner at North Bridge Venture Partners, where he finances and builds companies that make new products using chemistry, materials science, and/or materials engineering. He primarily focuses on very early stage ventures, including helping founders launch companies from initial formation.

Prior to joining North Bridge, Roberts cofounded several companies, including Arsenal Medical, Surface Logix, Nano-Terra, and Ancora. He has served in an executive and/or active board capacity for each of his companies.

Before starting his career as an entrepreneur, Roberts worked in business development at GelTex Pharmaceuticals (acquired by Genzyme). Prior to GelTex, he was responsible for new product and business development at Sentry Products, a life science venture wholly owned by Union Carbide Corporation (acquired by Dow Chemical).

Roberts is also very dedicated to developing medical products for developing nations. Along with Harvard University, he cofounded Diagnostics For All, Inc., a nonprofit organization that is developing a materials platform to make low cost diagnostics for poor and rural populations in developing nations. He currently serves as chairman of this organization.

Roberts serves on the advisory boards for MIT's Deshpande Center for Technological Innovation, Harvard's Nanoscale Science and Engineering Center, and Duke's School of Biomedical Engineering. In 1999, he was named one of the world's top 100 young entrepreneurs by MIT's Technology Review.

Roberts received his B.S. and Ph.D. in organic chemistry from Duke University and was a National Science Foundation fellow at Harvard University's departments of Chemistry and Chemical Biology. He earned his M.B.A. from the MIT Sloan School of Management.